← Trials/Trial dossier/NCT02664441
ECHO
CompletedPhase 3Results postedEnergy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
Glucagon-Like Peptide-1 Agonist Effects on Energy Balance in Hypothalamic Obesity
Lead sponsor
Assets
Exenatide / GLP-1 / incretin class catch-all
Listed sites
3
Recruiting sites
—
Enrollment
42
actual
Study population
Hypothalamic / syndromic obesity, Obesity / overweight
Key I/E criterion
•BMI ≥95
Primary endpoint
•BMI, change
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
Exclusion criteria
Endpoints (11)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
3 endpointsPercent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters².
Time frame:From baseline to 36 weeks
BMI, change
percent change from baseline, improvement
Posted result
| Group | Value (mean), percent change from baseline | 95% CI |
|---|---|---|
| Exenatide Once Weekly Extended-release | 1.7 | — |
| Matching Placebo | 3.5 | — |
Changes in Body Composition as Assessed by Body Fat Mass Using Dual Energy X-ray Absorptiometry (DEXA)
Time frame:At baseline and 36 weeks
Total fat mass
change from baseline, improvement
Posted result
| Group | Value (mean), kilograms | 95% CI |
|---|---|---|
| Exenatide Once Weekly Extended-release | 1.5 | — |
| Matching Placebo | 4.6 | — |
Changes of Energy Expenditure Assessed by Doubly Labeled Water Analysis
Time frame:Baseline and 36 weeks
total energy expenditure DLW
change from baseline, improvement
Posted result
| Group | Value (mean), kcals/day | 95% CI |
|---|---|---|
| Exenatide Once Weekly Extended-release | -17.8 | — |
| Matching Placebo | 146.3 | — |
Glycemic / diabetes
3 endpointsChanges in Fasting Glucose
Time frame:From baseline to 36 weeks
Fasting glucose, change
change from baseline, improvement
LOINC 1558-6
Posted result
| Group | Value (mean), mg/dL | 95% CI |
|---|---|---|
| Exenatide Once Weekly Extended-release | 7.4 | — |
| Matching Placebo | 3.7 | — |
Changes of Insulin Resistance Assessed by Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Time frame:From baseline to 36 weeks
HOMA-IR (insulin sensitivity)
change from baseline, improvement
Posted result
| Group | Value (mean), HOMA-IR score | 95% CI |
|---|---|---|
| Exenatide Once Weekly Extended-release | 3.5 | — |
| Matching Placebo | 2.2 | — |
Changes in Glucose 120 Minutes Following an Oral Glucose Tolerance Test
Time frame:From baseline to 36 weeks
Postprandial glucose
change from baseline, improvement
Posted result
| Group | Value (mean), mg/dL | 95% CI |
|---|---|---|
| Exenatide Once Weekly Extended-release | -12.4 | — |
| Matching Placebo | -3.4 | — |
Cardiometabolic biomarkers
3 endpointsChanges in HDL Cholesterol and Triglycerides Assessed by Fasting Lipids
Time frame:From baseline to 36 weeks
change from baseline, improvement
componentsHDL-C, change, Triglycerides, change
Posted result
| Group | Value (mean), mg/dL | 95% CI |
|---|---|---|
| Exenatide Once Weekly Extended-releaseHDL Cholesterol | 0.7 | — |
| Triglycerides | -0.6 | — |
| Matching PlaceboHDL Cholesterol | 0.6 | — |
| Triglycerides | 4.2 | — |
Analysis for HDL Cholesterol
Analysis for Triglycerides
Changes in Inflammation Assessed by C-reactive Protein (CRP)
Time frame:From baseline to 36 weeks
hs-CRP, change
change from baseline, improvement
LOINC 30522-7
Posted result
| Group | Value (mean), mg/dL | 95% CI |
|---|---|---|
| Exenatide Once Weekly Extended-release | 0.00 | — |
| Matching Placebo | 0.18 | — |
Changes of Circulating Leptin Levels
Time frame:From baseline to 36 weeks
Leptin, change
change from baseline, improvement
Posted result
| Group | Value (mean), ng/mL | 95% CI |
|---|---|---|
| Exenatide Once Weekly Extended-release | 1.4 | — |
| Matching Placebo | 11.8 | — |
Other clinical outcomes
2 endpointsChanges in Fat and Total Calorie Intake Assessed by Free Buffet Meal Analysis.
Time frame:From baseline to 36 weeks
change from baseline, improvement
componentsfat intake, total calorie intake
Posted result
| Group | Value (mean), grams | 95% CI |
|---|---|---|
| Exenatide Once Weekly Extended-releaseFat Intake | -9.5 | — |
| Total Calorie Intake | -287 | — |
| Matching PlaceboFat Intake | 14.5 | — |
| Total Calorie Intake | 224 | — |
Analysis for Fat Intake
Analysis for Total Calorie Intake
Changes of Energy Intake Assessed by Automated Self-Administered 24-Hour Dietary Recall (ASA24-Kids)
Time frame:Baseline and 36 weeks
change from baseline, descriptive
Posted result
| Group | Value (mean), kcals | 95% CI |
|---|---|---|
| Exenatide Once Weekly Extended-release | -62 | — |
| Matching Placebo | -210 | — |
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.